

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number  
**WO 01/25421 A2**

- (51) International Patent Classification<sup>7</sup>: C12N 15/10, 15/12, 15/62, 15/81, 1/19, C07K 14/47
- (21) International Application Number: PCT/US00/27900
- (22) International Filing Date: 6 October 2000 (06.10.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/157,996 6 October 1999 (06.10.1999) US  
60/181,892 11 February 2000 (11.02.2000) US  
60/182,373 14 February 2000 (14.02.2000) US
- (71) Applicant (for all designated States except US):  
**FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION** [US/US]; 106 Johnson Building, Innovation Park, 2035 East Paul Dirac Drive, Box 15, Tallahassee, FL 32310 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **TEEM, John, L.** [US/US]; 1515 Oldfield Drive, Tallahassee, FL 32312 (US).
- (74) Agents: **PACE, Doran, R.** et al.; Saliwanchik, Lloyd & Saliwanchik, Suite A-1, 2421 N.W. 41st Street, Gainesville, FL 32606-6699 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 01/25421 A2**

(54) Title: MATERIALS AND METHOD FOR DETECTING INTERACTION OF CFTR POLYPEPTIDES

(57) Abstract: The subject invention concerns materials and methods for detecting the interaction of CFTR proteins. In one embodiment, the method can be used to determine whether one CFTR polypeptide interacts with a second CFTR polypeptide. The subject invention also concerns materials and methods for screening for drugs or compositions that can restore or enhance interaction of CFTR proteins containing mutation(s) that reduce or prevent dimerization of the proteins. The assay of the present invention can be used to screen a large number of compounds in a high throughput format. The subject invention also pertains to host cells useful in the methods of the invention. The subject invention also concerns compositions and methods for treating patients afflicted with cystic fibrosis.

DESCRIPTIONMATERIALS AND METHODS FOR  
DETECTING INTERACTION OF CFTR POLYPEPTIDES

5

Cross-Reference to Related Applications

This application claims the benefit of U.S. Provisional Application No. 60/157,996, filed October 6, 1999; U.S. Provisional Application No. 60/181,892, filed February 11, 2000; and U.S. Provisional Application No. 60/182,373, filed February 14, 2000.

10

Background of the Invention

Cystic fibrosis (CF) is the most common genetic disease of Caucasians in North America, occurring at a frequency of approximately 1 in 2500 births (Welsh *et al.*, 1995). The disease results from defective function of the gene encoding the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein in a variety of tissues, including the pancreas and the lung epithelium. Riordan *et al.* (1989), Rommens *et al.* (1989) and Kerem *et al.* (1989) describe the cloning and sequencing of the CFTR gene. U.S. Patent No. 5,543,399 to Riordan *et al.* discloses the purification of CFTR protein.

15

Normal CFTR protein is a membrane protein that functions as a cAMP-regulated chloride channel. The  $\Delta F508$  mutation in the CFTR gene, which is characterized by a deletion of the phenylalanine amino acid at position 508 of the CFTR protein, is the defect associated with most cases of CF. A CFTR protein having the  $\Delta F508$  mutation does not exit the ER and proceed on to the plasma membrane (Cheng *et al.*, 1990; Gregory *et al.*, 1991). It has been found that the  $\Delta F508$  mutation causes the temperature-sensitive misprocessing of the mutant protein that prevents the protein from exiting the ER (Denning *et al.*, 1992).

20

25

The absence of CFTR protein in the pancreatic duct results in the blockage of the duct by a thick mucus that prevents pancreatic enzymes from passing from the pancreas to the intestine. Without treatment, CF patients decline as a consequence of malnutrition associated with insufficient pancreatic function. However, pancreatic enzymes may be

30

introduced into the diet of CF patients as a means of reversing the effects of pancreatic insufficiency.

5 Unlike in the pancreas, the absence of CFTR function in lung epithelium results in a severe lung disease that cannot be readily reversed or controlled by conventional treatment. Lack of CFTR function in the lung results in airway fluid with an altered ion composition, thereby creating a favorable environment for disease-causing bacteria to colonize the lung. Additionally, mucus secreted into the lung becomes thick and viscous, preventing normal clearing of the bacteria from the airways. The chronic bacterial infection leads to destruction of lung tissue and loss of lung function. Current treatments  
10 for CF lung disease involve physical therapy to aid mucus clearance and antibiotic therapy to treat the lung infection. Although these treatments slow the progression of disease, they do not reverse it. Patients with CF consequently die prematurely, usually by the age of 30.

15 CF cells lack CFTR chloride channel activity because they have mutant CFTR genes that encode a defective CFTR protein. Thus, providing a patient with a copy of a normal human CFTR gene by way of gene therapy methods may provide an alternative to conventional therapies for the treatment of CF. Gene therapy strategies for the treatment of CF thus involve delivery of a normal wildtype human CFTR gene to mutant CF epithelial cells within the lung to restore normal CFTR chloride channel activity. Gene  
20 transfer of the CFTR gene can be accomplished by several different delivery methods. Recombinant viral vectors containing the wildtype CFTR gene provide one potential means to deliver the CFTR gene to CF cells. For example, recombinant adenovirus containing the wildtype CFTR gene have been shown to efficiently transfer the wildtype CFTR gene into CF epithelium, and correct the chloride channel defect (Welsh *et al.*,  
25 1994; Zabner *et al.*, 1993). However, high doses of virus are generally required to obtain an efficacious response, which in time can cause inflammation resulting from the immune response to the viral proteins. Other viruses that might be used for CF gene therapy include AAV (Adeno-associated virus) (Flotte *et al.*, 1994), retrovirus and lentivirus. The use of these viruses for gene therapy is also limited by the immune response to the high  
30 titer doses required for an efficacious response.

Gene transfer can also be achieved by transfection of CF cells by lipid-DNA complexes composed of plasmid DNA containing the CFTR cDNA in association with cationic or neutral lipids (Zabner *et al.*, 1997). Gene therapy utilizing lipid-DNA complexes is a potential alternative to the use of viral vectors and presents a lower risk for an associated inflammatory immune response. However, gene transfer with lipid-DNA complexes is inefficient, so that only a small fraction of cells receive the therapeutic gene. As a consequence, only a very limited correction of the chloride channel defect is possible.

Another alternative for CF therapy is to identify drugs that have efficacy in treating the disease. However, the process of identifying potential drugs typically involves the screening of large numbers of compounds from a chemical library. Thus, the assay used to screen the library for active compounds must be specific for a desired activity, as well as rapid and cost effective. However, current drug screening strategies using mammalian cells and assays for CFTR chloride conductance are costly and labor intensive. Thus, there remains a need in the art for a means for rapidly screening potential drugs for the treatment of CF from among the hundreds of thousands of chemicals that can be tested.

#### Brief Summary of the Invention

The subject invention concerns materials and methods for detecting the interaction of CFTR proteins. In one embodiment, the method can be used to determine whether one CFTR NBD1 polypeptide interacts with a second CFTR NBD1 polypeptide using a yeast dual hybrid assay. The subject methods can be used to determine whether mutations to the CFTR polypeptide reduce or eliminate dimerization of the CFTR polypeptides. The present methods can also be used to screen and identify revertant mutations that restore dimerization of a mutant CFTR polypeptide, as well as mutations that enhance dimerization and CFTR activity greater than that of wildtype protein.

The subject invention also provides materials and methods for efficiently identifying and screening for compounds, drugs and other such compositions that facilitate proper dimerization of the CFTR polypeptides. Compounds identified using materials and methods of the present invention are candidate agents for use in treating patients having CF. In one embodiment, a yeast dual hybrid assay is used to identify compounds that can restore dimerization of a protein comprising a region of a CFTR polypeptide having a

mutation, such as  $\Delta F508$ , that prevents dimerization. The assay methods of the present invention can be used to evaluate a large number of compounds in a high throughput format. The use of a yeast growth bioassay exemplified herein is fast and inexpensive in comparison to current screening procedures that involve mammalian cells and assays for CFTR channel activity.

The subject invention also concerns compositions and methods for treating CF. The compositions of the invention can be used to restore, promote or enhance the dimerization of CFTR protein and/or its exit from the ER and proper localization in the cell.

#### Brief Description of the Drawings

**Figure 1** shows an example of a plate with a positive-testing plant leaf disc on selective media using a yeast two-hybrid assay of the present invention.

**Figures 2A-2C** show growth of two-hybrid yeast strains containing wildtype and mutant CFTR NBD1. The yeast strain YRG2 was transformed with pADGAL4 and pBDGAL4 constructs containing wildtype and mutant CFTR NBD1 as indicated. Each strain was grown in synthetic complete media lacking leucine and tryptophan, and equal aliquots of cells in 10-fold dilutions were spotted to synthetic complete media lacking leucine, tryptophan and histidine. Dilutions for each strain proceed from right to left, with the spots from most dilute cultures corresponding to the tapered end of the triangle. Plates were incubated at either 21°C (Figure 2A) or 37°C (Figure 2B) (for 3 days and 5 days respectively). Glycerol was added to the media to a final concentration of 1.5 M as indicated (1.5 M Glyc) (Figure 2C).

**Figure 3** shows correction of the  $\Delta F508$  dimerization defect by I539T and G550E. The yeast strain YRG2 (Stratagene) was transformed with pADGAL4 and pBDGAL4 constructs containing wildtype and mutant CFTR NBD1 as indicated. Each strain was grown in synthetic complete media lacking leucine and tryptophan, and equal aliquots of cells in 10-fold dilutions were spotted to synthetic complete media lacking leucine, tryptophan and histidine. Dilutions for each strain proceed from right to left, with the spots from most dilute cultures corresponding to the tapered end of the triangle. Plates were incubated at 37°C for 5 days.

**Figure 4** shows the effect of the revertant mutations I539T and G550E on CFTR $\Delta$ F508 chloride channel activity in FRT stable cell lines. FRT stable cell lines were seeded in permeable Millicell supports (Millipore) at a density of  $2.5 \times 10^5$  cells/  $\text{cm}^2$ . After 6 to 7 days monolayers were mounted on Ussing chambers and the  $\Delta I^{\text{Cl}}$  was recorded 5 min after stimulation with 10 mM forskolin and 0.1 mM IBMX (Sheppard *et al.*, 1994).

#### Brief Description of the Sequences

**SEQ ID NO:1** is a primer for PCR amplification of a fragment of a cDNA encoding CFTR.

**SEQ ID NO:2** is a primer for PCR amplification of a fragment of a cDNA encoding CFTR.

**SEQ ID NO:3** is a polynucleotide sequence that encodes a wildtype CFTR protein.

**SEQ ID NO:4** is an amino acid sequence of a wildtype CFTR protein.

#### Detailed Disclosure of the Invention

The subject invention concerns materials and methods for detecting the interaction of cystic fibrosis transmembrane conductance regulator (CFTR) proteins. The method can be used to determine whether one CFTR polypeptide interacts with a second CFTR polypeptide. Preferably, the CFTR polypeptides are mammalian. More preferably, the CFTR polypeptides are human CFTR polypeptides. The methods of the present invention are based on the discovery that the wildtype CFTR protein forms dimers, and that dimerization is essential for the exit of the CFTR protein from the endoplasmic reticulum (ER). As described herein, a method of the present invention for detecting or determining the interaction of a first CFTR polypeptide with a second CFTR polypeptide comprises contacting the CFTR polypeptides and determining whether the polypeptides interact using a system where if interaction does occur then a detectable signal or change is induced in the assay system. In one embodiment, dimerization involves an association of the first nucleotide binding fold (NBD1) of one CFTR monomer with the NBD1 of

another CFTR monomer. The methods of the present invention can model the temperature-sensitive misprocessing of mutant CFTR proteins.

In one embodiment, a method of the invention for detecting or determining the interaction of a first CFTR polypeptide with a second CFTR polypeptide comprises (a) providing a first fusion protein comprising all or a portion of a first CFTR protein and a DNA binding domain of a transcriptional activator that can bind to a site on a detectable reporter gene; (b) providing a second fusion protein comprising all or a portion of a second CFTR polypeptide and a transcriptional activation domain of a transcriptional activator that can activate transcription of the detectable reporter gene; (c) contacting the first fusion protein and the second fusion protein under conditions where if the first fusion protein and the second fusion protein interact then the interaction causes the transcriptional activation domain to activate transcription of the detectable reporter gene; and (d) detecting transcription of the detectable reporter gene or expression of the detectable reporter gene product. By “detectable gene” it is meant that expression of the gene or its gene product can be detected. The detectable gene can be engineered with sequences that bring the gene under control of the transcriptional activator. For example, where the GAL4 transcriptional activator is to be used, the UAS<sub>G</sub> (upstream activation site, galactose) site (Keegan *et al.*, 1986; Ma and Ptashne, 1987) can be incorporated upstream of the transcription start site of the detectable gene.

In a preferred embodiment, the fusion proteins are provided in a double transformant host cell, such as a yeast cell. The polynucleotide sequences encoding the fusion proteins can be incorporated into suitable expression vectors or plasmids, such as pAD-GAL4 or pBD-GAL4 for use in yeast cells. Other suitable vectors and plasmids are known in the art and can be readily selected by the ordinarily skilled artisan. Once the sequences encoding the fusion proteins are inserted in the vector or plasmid, the vector or plasmid can be incorporated into the host cell using standard methods, resulting in a double transformant host cell.

In additional embodiments, the interaction of a first CFTR polypeptide with a second CFTR polypeptide can be detected in a host cell by the interaction of signal transduction fusion proteins, or by the interaction of proteins resulting in cleavage of a ubiquitin fusion protein. These methods of detecting protein:protein interactions, by SOS

recruitment (Aronheim *et al.*, 1997) or by a split ubiquitin sensor (Johnsson and Varshavsky, 1997), respectively, are well known to those skilled in the art and are contemplated within the scope of methods of the present invention. The preferred host cell for these embodiments is yeast. In another embodiment, the interaction of a first CFTR polypeptide with a second CFTR polypeptide is detected by interaction of signal transduction fusion proteins within a bacterial cell. Methods for detecting protein:protein interactions in bacteria are also known by those skilled in the art (Karimova *et al.*, 1998).

The CFTR portion of the fusion protein can contain one or more mutations of the wildtype amino acid sequence. The mutations contemplated can include amino acid substitutions, deletions and insertions. Any mutation, including mutations to CFTR already known in the art and associated with CF, can be prepared in the sequence of the CFTR polypeptide and used in the methods of the present invention. The CFTR protein of the fusion protein can include the entire coding sequence of the protein or a fragment thereof.

In one embodiment, dual hybrid systems can be used in the methods of the present invention. Dual hybrid systems are described in U.S. Patent Nos. 5,283,173 and 5,468,614, which are herein incorporated by reference. Dual hybrid reagents are also available from commercial suppliers such as CLONTECH Laboratories (Palo Alto, CA) and Stratagene (La Jolla, CA). In a preferred embodiment, all or a portion of a first human or mammalian CFTR gene is cloned into a suitable plasmid that, when expressed in a host cell, provides a hybrid protein comprising a first CFTR protein, or a variant or fragment thereof, and a DNA-binding domain of a transcriptional activator that can bind to a site on a detectable gene in the host cell. All or a portion of a second human or mammalian CFTR gene is also cloned into a suitable plasmid that, when expressed in the host cell, provides a hybrid protein comprising a second CFTR protein, or a variant or fragment thereof, and a transcriptional activation domain that can activate transcription of the detectable gene in the host cell when the transcriptional activation domain is brought into close proximity with the detectable gene. Preferably, the first and second CFTR polypeptides are identical; however, the use of first and second CFTR polypeptides that are different, for example in amino acid sequence or length, is also contemplated within the scope of the present invention. The expression plasmids encoding the hybrid



proteins can be introduced into a host cell using standard methods known in the art, such as electroporation or transfection by calcium phosphate precipitation. Preferably, the portion of the CFTR protein expressed in the hybrid proteins includes the first nucleotide binding domain (NBD1), or a functional fragment thereof, of human CFTR. The polynucleotides encoding the first and second fusion proteins are exposed to conditions where the fusion proteins are expressed. If the CFTR polypeptides of the expressed hybrid proteins interact, then the DNA binding domain and transcriptional activation domain of the transcriptional activator are brought into close proximity sufficient to cause transcription of the detectable gene. Where transcription or expression of the detectable gene is observed, this is indicative of interaction of the CFTR portion of the fusion proteins.

As taught herein, wildtype human CFTR used in the subject dual hybrid methods interact and result in transcription of the detectable gene in the host cell in the dual hybrid embodiment described herein. Mutations that reduce or prevent dimerization of CFTR proteins can be identified using the methods and materials of the present invention because these mutant CFTR proteins do not interact and, therefore, transcription of the detectable gene in the host cell does not occur. In an exemplified embodiment, the  $\Delta F508$  mutation is shown to interfere with CFTR interaction.

In those embodiments where protein:protein interaction is indicated by transcription of a detectable reporter gene, then any suitable DNA-binding domain and transcriptional activation domain can be used in the subject invention as long as the domains can be used to activate transcription of the detectable gene when the DNA-binding domain and transcriptional activation domain are brought into sufficiently close proximity to each other. The DNA-binding domain and transcriptional activation domain can be derived from the same protein or from different proteins. Examples of suitable domains are known in the art and can be obtained from, for example, yeast GAL4, GCN1 and ADR. In an exemplified embodiment of the invention, the domains are derived from yeast GAL4 protein. Non-yeast DNA-binding and/or transcriptional activation domains are also contemplated for use in the present invention and include, for example, a DNA-binding domain derived from the prokaryotic LexA protein and an 88-residue peptide (B42) capable of activating transcription (CLONTECH Laboratories, Palo Alto, CA).

DNA-binding domains and transcriptional activation domains for use in mammalian host cells are also available.

The host cells can be any suitable prokaryotic or eukaryotic cell, including bacterial, yeast or mammalian cells. Preferably, the host cell is a yeast cell. More preferably, the yeast cell is *Saccharomyces*.

The interaction of the first hybrid protein and the second hybrid protein in the host cell causes a measurably greater expression of the detectable gene than that observed where the first hybrid protein and the second hybrid protein do not interact or interact at a reduced level. The detectable gene used in the present invention can be any gene whose transcription can be detected when the detectable gene is expressed as a result of the interaction of the CFTR fusion protein containing the DNA-binding and transcriptional activation domains. Typically, expression of the gene is detected directly or indirectly by detecting the expression product of the detectable gene. For example, the detectable gene may provide for drug resistance or encode an enzyme or other product that can be readily measured or detected. Such measurable activity may include providing the host cell with the ability to grow only when the detectable reporter gene is expressed, or providing for the presence of detectable protein or enzyme activity only when the detectable reporter gene is expressed. Suitable detectable genes are well known in the art. Examples of detectable genes include *lacZ* (which encodes  $\beta$ -galactosidase), *HIS3*, *LEU2* and the like. In an exemplified embodiment, the detectable gene is the *HIS3* gene. Host cells can be selected that lack or are defective in the detectable gene activity. Thus, if host cells that are normally unable to synthesize histidine are grown on a medium lacking histidine, then only those cells that are expressing the *HIS3* gene as a result of CFTR protein interaction can grow, or at least grow at an efficient rate, on the medium lacking histidine. Growth of cells only in the presence of a test drug or compound is indicative that the drug or compound has restored interaction of the CFTR proteins. Methods for detecting protein interactions mediated by small molecule small ligands have been described in the art (Berlin, 1997).

In an exemplified embodiment of the invention, the NBD1 region of CFTR (containing amino acids 351-650) was cloned into two plasmids, pBDGAL4 and pADGAL4, (Stratagene) that produce the NBD1-DNA binding domain fusion protein and

the NBD1-activation domain fusion protein, respectively, when co-expressed in yeast. When these proteins associate and form a dimer in yeast, transcription of the detectable gene occurs. The dimerization of the fusion proteins is required for growth of host cells in selective media. If the NBD1 coding region of one or both of the two plasmids is modified to contain the  $\Delta F508$  mutation and then expressed in yeast, the growth of the yeast is substantially impaired upon the selective media. The impaired growth of the yeast cells on the selective media results from the mutation(s) which prevent the dimerization of the proteins.

The subject invention also concerns unique host cells that can be used to model wildtype CFTR protein dimerization, and which can also be used to model the effect of CF mutations on dimerization. In a preferred embodiment, the host cells are yeast cells, such as *Saccharomyces cerevisiae* or other suitable cells. The host cells are genetically engineered to express a hybrid protein that comprises a first human or other mammalian CFTR protein fused to a DNA binding domain of a transcriptional activator that can bind to a site on a detectable gene in the host cell. The host cells are also engineered to express a second hybrid protein that comprises human or mammalian CFTR protein fused to a transcriptional activator domain that can activate transcription of the detectable gene in the host cell when the transcriptional activator domain is brought into sufficiently close proximity with the detectable gene in the host cell. In a preferred embodiment, the portion of the CFTR protein expressed in the hybrid proteins is the first nucleotide binding domain (NBD1) of a human or other mammalian CFTR protein. In another embodiment, the first and/or second human or other mammalian CFTR protein that forms part of a hybrid protein in the host cell contains a mutation, such as, for example, the  $\Delta F508$  mutation. Using the host cells of the present invention, one can determine whether a particular mutation or mutations of one or both of the CFTR protein(s) will effect dimerization of the CFTR proteins. The host cells can be used in the methods of the present invention to detect interaction of CFTR proteins and to screen for drugs or compounds that can restore or enhance dimerization of CFTR proteins that contain mutations impacting dimerization.

The present invention also concerns methods and materials for screening and identifying compositions that restore or enhance interaction of CFTR proteins. In one

embodiment, a method of the present invention for identifying a compound that facilitates interaction of CFTR polypeptides comprises contacting a host cell with the compound. Preferably, the host cell comprises a polynucleotide encoding a fusion protein comprising all or a portion of a first CFTR protein and a DNA binding domain of a transcriptional activator that can bind to a site on a detectable gene, and a polynucleotide encoding a fusion protein comprising all or a portion of a second CFTR polypeptide and a transcriptional activation domain of a transcriptional activator that can activate transcription of the detectable gene; however, the first or second CFTR polypeptides, or both the first and second polypeptides, used in the subject method comprise a mutation that reduces or prevents interaction of said fusion proteins. The polynucleotide encoding the first CFTR polypeptide and the second CFTR polypeptide are expressed in the host cell under conditions in which the detectable gene is expressed when the first CFTR polypeptide and the second CFTR polypeptide interact. If, in the presence of the test compounds, the detectable gene is expressed in the host cell at a level greater than the level of expression observed in the host cell in the absence of the compound, then that compound can be used in restoring interaction and dimerization of mutant CFTR polypeptides.

If either the first or second CFTR polypeptides, or both the first and second polypeptides used in the subject method comprise the temperature-sensitive  $\Delta F508$  mutation, interaction of the fusion proteins will be reduced when cells are incubated at the nonpermissive temperature. The polynucleotide encoding the first CFTR polypeptide and the second CFTR polypeptide are therefore expressed in the host cell incubated at the nonpermissive temperature resulting in impaired interaction between the first CFTR polypeptide and the second CFTR polypeptide, and reduced expression of the detectable gene. If a compound is added to the host cell incubated at the nonpermissive temperature, and the expression of the detectable gene is greater than the expression of the detectable gene in the host cell incubated at the nonpermissive temperature in the absence of the compound, then that compound can be used in restoring dimerization of CFTR polypeptides comprising the  $\Delta F508$  mutation.

The present invention concerns methods for screening chemical compounds for drug candidates with activity to correct the dimerization defect associated with mutant

CFTR NBD1 containing the  $\Delta F508$  mutation. In the preferred embodiment, the YRG2- $\Delta F$  strain is spread at low density ( $5.0 \times 10^6$  cells per plate) on the surface of selective yeast media in a petri dish plate. The media is SC-LEU-TRP-HIS (yeast nitrogen base w/o amino acids, and supplemented with all amino acids except leucine, tryptophan and histidine). Onto the surface of the plate is then placed one or more filter paper discs soaked in a solvent solution containing a test compound. The compound can be any small molecule of synthetic or natural product origin, or a natural product extract, and the solvent can be any suitable solvent with the preferred solvent being DMSO. The plate is incubated for one to three days at  $37^\circ\text{C}$ . A compound that demonstrates activity to correct the NBD1 $\Delta F508$  dimerization defect will diffuse into the media and cause the YRG2- $\Delta F$  yeast strain to grow at an increased rate in the proximity of the filter paper disc containing the active compound. The enhanced growth of the YRG2- $\Delta F$  yeast around a filter paper disc thus indicates the presence of an active compound within the test disc. If the sample tested is a pure compound, the compound can then be analyzed further in secondary assays to determine its activity to restore CFTR $\Delta F508$  cAMP-stimulated chloride channel activity in mammalian cells expressing CFTR $\Delta F508$  (Sheppard *et al.*, 1994). If the sample being tested is a complex mixture of chemical compounds in a natural product extract, the extract can be fractionated by standard techniques and the fractions assayed using the YRG2- $\Delta F$  yeast as described above to identify fractions with the purified active compound. In another embodiment of the method, media used in screening compounds can contain 3-amino-2,3,4-triazole at a concentration of about 1.5mM to make the assay more selective for compounds with high activity. In yet another embodiment of the method, the screening of compounds can be done using YRG2- $\Delta F$  grown in SC-LEU-TRP-HIS broth in microtiter plates incubated at  $37^\circ\text{C}$  with test compounds added to the liquid culture. Compounds that correct the dimerization defect of YRG2- $\Delta F$  in this format will be detectable by detection of enhanced turbidity of individual micotiter wells containing an active compound.

The present invention also concerns plants and isolated extracts thereof that contain compounds or compositions that facilitate, enhance or restore dimerization of CFTR polypeptides. Plants that have tested positive for compounds capable of facilitating dimerization of CFTR polypeptides include *Trichilia* species. The present invention also

concerns the compounds identified as facilitating, enhancing or restoring CFTR dimerization. Active compounds identified using the yeast mating and two-hybrid assays described herein can be purified from plants using standard biochemical function methods known in the art.

5           The present invention also concerns methods for screening plants for compounds of interest. In one embodiment, fragments of plant leaves are prepared from a plant to be tested and screened for bioactive compounds using a yeast-based assay of the present invention. A plant containing a compound that facilitates or enhances dimerization of mutant CFTR polypeptides is indicated by growth of yeast on a selective media. The  
10           methods described herein for screening the plants are efficient because a large number of plants can be tested on one petri dish and the results can be determined within a few days.

          As exemplified herein, plants can be screened for bioactive compounds using a yeast two-hybrid assay according to the present invention. In the two hybrid methods of the invention, plants are screened using a yeast strain which contains a CF mutation that  
15           prohibits or interferes with the dimerization of CFTR proteins. In the absence of dimerization, the strain cannot grow on a selective media, such as, for example, a histidine-deficient media when the host cells are unable to synthesize histidine. Thus, growth of the yeast around plant tissue will be observed when the tissue contains a compound that enhances dimerization between the CFTR polypeptides in the yeast strain.

20           A composition that restores the ability of the hybrid proteins containing mutations in the CFTR proteins to interact can then be secondarily tested for activity to restore cAMP-stimulated chloride channel function in mammalian cells expressing CFTR having the same mutation. Drugs and compounds that restore dimerization and function *in vitro* can be further evaluated to confirm *in vivo* efficacy in treating clinical CF disease.  
25           Thus, the subject invention also concerns materials and methods for identifying compounds useful in treating CF.

          The subject invention also concerns methods for treating CF by providing a drug or other compound that restores, promotes or enhances the dimerization of CFTR protein and/or its exit from ER. In one embodiment, an effective amount of a drug or compound  
30           identified using the methods of the present invention is administered to a CF patient. The amount of the drug or compound to be administered can be readily determined by the

ordinarily skilled clinician having the benefit of the subject disclosure. If the drug or compound is a protein, then the drug or compound can also be provided to a CF patient by gene therapy methods. A polynucleotide sequence encoding the protein can be delivered to CF cells of a patient either *in vivo* or *ex vivo* using standard gene transfer methods and constructs. The drug or compound is expressed in the CF cell and thereby promotes dimerization of the mutant CFTR protein to enable the CFTR protein to properly localize and function as in a normal, non-CF cell.

The subject invention also concerns drugs, compounds, polypeptides and biologically active fragments thereof, antibodies or antigen binding fragments thereof, polynucleotides and other agents identified using the methods of the invention that restore, promote or enhance the *in vivo* dimerization of CFTR protein and/or its exit from ER in a cell. The drugs and compounds of the present invention can be used to treat CF patients according to the methods described herein.

The subject invention also concerns methods for screening for second site mutations that correct the defect in mutant CFTR. For example, using the methods of the subject invention, one can screen for mutations that correct a CFTR gene carrying the  $\Delta F508$  mutation. In one embodiment, the present invention can be used to screen for second site mutations that provide increased expression and function of CFTR that is greater than that observed for normal wildtype CFTR expression. The present invention also concerns mutant CFTR genes that contain second site mutations that correct the CF defect and provide increased expression and function of CFTR substantially the same as or greater than normal human wildtype CFTR.

All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety to the extent they are not inconsistent with the explicit teachings of this specification.

Following are examples which illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

### Materials and Methods

Construction of plasmids and transformed yeast cells. The HYBRIZAP Two-Hybrid System (Stratagene, LaJolla, CA) was used for construction of gene fusions of the GAL4 activation domain and GAL4 DNA binding domain to CFTR NBD1. Fusion genes constructed with plasmids pAD-GAL4 and pBD-GAL4 were expressed in yeast strain YRG2 (genotype: *Mat α, ura3-52, his3-200, ade2-101, lys2-801, trp1-901, leu2-3, 112, gal4-542, gal80-538, LYS2::UAS<sub>GAL1</sub>-TATA<sub>GAL1</sub>-HIS3 URA::UAS<sub>GAL4 17mers(x3)</sub> TATA<sub>CYC1</sub>-lacZ*). The plasmids pSWICK-CFTR (obtained from Dr. Michael Welsh, University of Iowa) and pSwick-CFTR $\Delta$ F508 contain the full length wildtype CFTR cDNA and mutant CFTR cDNA (containing  $\Delta$ F508) respectively. Derivatives of these plasmids (pSwick-BXWT and pSwick BX $\Delta$ F respectively) that contain a Sma I restriction site at CFTR nucleotide position 1626 and a Xho I site at nucleotide position 1808 were constructed by site-directed mutagenesis.

First, a DNA fragment containing CFTR amino acids T351-F492 was produced using pSwick-BXWT plasmid DNA as template and the primers PRNBD1-R1 (5'-CGCGGAATTCACCTCGGCAATTTCCC-3') (SEQ ID NO:1) and PRNBD1-PST (5'-GCGCCTGCAGTTAAGAACAGAATGAAAT-3') (SEQ ID NO:2) in the polymerase chain reaction (PCR). The resulting 142 bp DNA fragment contained an Eco RI restriction endonuclease site preceding the CFTR amino acid T351 and a Pst I site following CFTR amino acid S492. The fragment was restricted with EcoRI and Pst I restriction endonucleases, and ligated into the unique Eco RI and Pst I restriction sites within pAD-GAL4 to produce pADPRNBD1 in which CFTR amino acids are T351-S492 joined in frame to the pAD-GAL4 transcription activation domain. A second GAL4-CFTR fusion plasmid was constructed in which a 951 bp HpaI-TaqI DNA fragment from pSwick-BXWT (containing CFTR amino acids R334-F650, and with the ends of the fragment made blunt by kenow fragment) was purified from an agarose gel and ligated into the Sma I site of plasmid pBDGAL4 to produce PBD-N. The pBD-N plasmid DNA was then cut with Eco RI and Bam HI and the vector molecule purified from an agarose gel. The purified Eco RI-Bam HI pBD-N vector molecule was then ligated to an Eco RI-Bam HI restriction fragment from pADPRNBD1 (containing amino acids T351-S492 of CFTR), producing pBDPN-WT. The pBDPN-WT plasmid contains CFTR amino acids



T351-F650 fused in frame to the GAL4 DNA binding domain. This region contains the predicted cytosolic region that precedes NBD1, the NBD1 region, and also a segment that had previously been ascribed to the R domain. The plasmid pBDPN-WT also contains the TRP1 gene of yeast, and replication origin from the yeast 2 $\mu$  plasmid. The Eco RI-Pst I fragment from pBDPN-WT (containing CFTR amino acids T351-F650) was then cloned  
5 into the EcoRI and Pst sites of pADGAL4, producing pADPN-WT. pADPN-WT contains CFTR amino acids T351-F650 fused in frame to the GAL4 activation domain. The pADPN-WT plasmid also contains the LEU2 gene of yeast and the replication origin of the yeast 2 $\mu$  circle. Both plasmids pBDPN-WT and pADPN-WT were introduced by  
10 transformation into yeast cell strain YGR-2 to produce cells designated as YRG2-WT.

A plasmid identical to pBDPN-WT, but containing the  $\Delta$ F508 mutation (pBDPN $\Delta$ F) was constructed by cutting pBDPN-WT with Bam HI and Xho I, and replacing the approximately 180 bp Bam HI-Xho I fragment (containing the wildtype CFTR region P499-R560) with the corresponding Bam HI-Xho I fragment from pSwick-  
15 BX $\Delta$ F containing the  $\Delta$ F508 mutation. Similarly, a plasmid identical to pADPN-WT, but containing the  $\Delta$ F508 mutation was constructed. Both plasmids pBDPN- $\Delta$ F and pADPN- $\Delta$ F were introduced by transformation into yeast cell strain YGR-2 to produce cells designated as YRG2- $\Delta$ F.

#### 20 Example 1 – Interaction of CFTR proteins

A protein:protein interaction between the CFTR NBD1 polypeptide segment in each GAL4 fusion protein encoded by pBDPN-WT and pADPN-WT plasmids in YRG2-WT is expected to activate transcription of the HIS3 reporter gene in yeast, resulting in a HIS<sup>+</sup> phenotype. Accordingly, the YRG2-WT strain was streaked onto agar plates  
25 containing synthetic complete media lacking tryptophan, leucine, and histidine (SC-HIS, -LEU, -TRP) to determine the HIS phenotype. As shown in Table 1, the YRG2-WT strain was phenotypically HIS<sup>+</sup> at all temperatures tested (21°C, 30°C, and 34°C), indicating that the two NBD1 fusion proteins associated *in vivo* to activate GAL4 transcription. The YRG2 strain containing either the pBDPN-WT plasmid or the  
30 pADPN-WT plasmid alone was unable to grow on media lacking histidine. The wildtype CFTR NBD1 segment is thus able to self-associate and form dimers at 21°C, 30°C and

34°C. When grown in liquid culture media (SC-HIS, -LEU, -TRP), at 21°C, 30°C, and 34°C, the YRG2-WT yeast strain had a generation time of approximately 300, 138 and 420 minutes, respectively.

5 When the YRG2-ΔF strain was streaked onto solid media (SC-HIS, -LEU, -TRP) and incubated at 21°C, colonies formed within three days (Table 2). The YRG2-ΔF colonies were approximately the same size as colonies produced by YRG2-WT grown under the same conditions. However, when YRG2-ΔF was streaked onto SC-HIS-LEU-TRP solid media and incubated at 30°C, only small colonies were apparent after three days (substantially smaller in size than YRG2-WT colonies grown under the same growth  
10 conditions). Colonies were not apparent (or were detectable only as extremely small micro-colonies) when YRG2-ΔF was streaked onto solid SC-HIS, -LEU, -TRP media and incubated at 34°C. The ΔF508 mutation thus conferred a temperature-sensitive HIS<sup>+</sup> phenotype to the yeast strain containing pADPN-ΔF and pBDPN-ΔF. To further enhance the temperature-sensitive HIS<sup>-</sup> colony phenotype of the YRG2-ΔF strain relative to the  
15 YRG2-WT strain, it is advantageous to incorporate 3-amino-1,2,4-triazole at a concentration of 1.5mM into the SC-HIS-LEU-TRP media. The addition of 1.5mM 3-amino-1,2,4-triazole to the SC-HIS-LEU-TRP media prevents colony formation of the YRG2-ΔF strain when grown at 30°C for three days, but does not inhibit colony formation of the YRG2-WT strain grown under the same conditions.

20 The temperature-sensitive growth HIS<sup>+</sup> phenotype was also observed when YRG2-ΔF was grown in SC-HIS-LEU-TRP liquid culture media at 21°C, 30°C and 34°C (Table 2). When incubated at 21°C, the generation time of YRG2-ΔF was observed to be approximately 400 minutes, which is comparable to the generation time of YRG2-WT under the same growth conditions. However, when incubated at 30°C, the  
25 generation time of YRG2-ΔF was approximately 1380 minutes, which is substantially longer than the generation time of the YRG2-WT strain (138 minutes) at this temperature. The generation time of YRG2-ΔF incubated at 34°C (>4320 minutes) was also increased substantially as compared to YRG2-WT (420 minutes). These results indicate that the ΔF508 mutation interferes with the dimerization of NBD1 in a temperature-sensitive  
30 manner. Further, the effect of the ΔF508 mutation on YRG2-ΔF growth rate is analogous to the temperature-sensitive effect of ΔF508 on the processing of CFTRΔF508, indicating

the folding defect of CFTR $\Delta$ F508 has been faithfully modeled with the YRG2- $\Delta$ F yeast strain.

5

<b>Table 1.</b>			
Yeast Strain YRG2-WT			
	21°C	30°C	34°C
Colony formation on solid agar media after 3 days (SC-HIS, -LEU, -TRP)	+	+	+
10 Generation time (min.) when grown in liquid culture medial (SC-HIS, -LEU, -TRP)	300	138	420

15

<b>Table 2.</b>			
Yeast Strain YRG2- $\Delta$ F			
	21°C	30°C	34°C
20 Colony formation on solid agar media after 3 days (SC-HIS, -LEU, -TRP)	+	+/-	-
Generation time (min.) when grown in liquid culture medial (SC-HIS, -LEU, -TRP)	441	1380	>4320

25 Example 2 – Screening of Plants for Compounds Using the Yeast Two-Hybrid Assay

The YRG- F yeast strain used for this assay expresses two hybrid genes consisting of the N-terminal nucleotide binding domain of CFTR which contains the cystic fibrosis causing mutation  $\Delta$ F508 (NBD1  $\Delta$ F508), fused to the DNA binding domain of the GAL4 transcription activator (GAL4BD) in the first hybrid and to the GAL4 activation domain (GAL4AD) of the second hybrid.

30

The yeast strain is used as a bioassay tool for the detection of dimerization of the NBD1  $\Delta$ F508 domain of CFTR. In the mutant human CFTR chloride channel containing the  $\Delta$ F508 mutation, defective dimerization of the channel is impaired in a temperature-sensitive manner. Similarly, the dimerization of NBD1  $\Delta$ F508 in the YRG2- $\Delta$ F strain (the

35

binding of the GAL4BD-NBD1  $\Delta$ F508 fusion protein to the GAL4AD-NBD1  $\Delta$ F508 fusion protein) is temperature-sensitive. In the absence of NBD1  $\Delta$ F508 dimerization, the YRG2- $\Delta$ F strain cannot activate transcription of the HIS3 gene which prevents the strain from growing on selective media lacking histidine at temperatures higher than 21°C.

5           Because the YRG2- $\Delta$ F strain is not capable of growing in a medium lacking the amino acid histidine as a result of defective NBD1  $\Delta$ F508 dimerization, it can be used in a plate assay to screen for compounds, such as those present in plant leaves, that promote the association of the two NBD1  $\Delta$ F508. The association of NBD1  $\Delta$ F508 brings the Gal4 activation and DNA binding domain together, thereby activating HIS3 synthesis and  
10           permitting growth of the yeast in a medium lacking histidine.

          To use the YRG2- $\Delta$ F strain for screening purposes, a lawn of the YRG2- $\Delta$ F strain is spread onto selective media. This media contains yeast nitrogen base and all amino acids except for histidine, leucine, and tryptophan. The media also contains 3-amino 1,2,4-triazole at a concentration of 1.5 mM. The addition of the 3-amino 1,2,4-triazole  
15           to the media inhibits the residual HIS3 enzyme activity present in the YRG2- $\Delta$ F strain, thereby producing a tighter his- phenotype of the YRG2- $\Delta$ F strain on media lacking histidine. The YRG2- $\Delta$ F strain was added to the selective media, along with leaf discs to be screened and the plates were incubated at 30°C for several days. Increased growth of the YRG2- $\Delta$ F strain around a leaf disc indicates the presence of a compound in the disc that reversed the  $\Delta$ F508 dimerization defect. Figure 1 shows a plate containing a leaf disc  
20           (denoted by arrow) that was positive for the presence of compounds that permitted growth of the YRG2- $\Delta$ F strain in the two-hybrid assay.

### 25           Example 3 – Analysis of NBD1 protein:protein interactions by the yeast two-hybrid system

          Because the  $\Delta$ F508 mutation occurs in the NBD1 domain of CFTR, the dimerization of CFTR proteins may involve NBD1 and, thus, the  $\Delta$ F508 mutation may result in defective NBD1 dimerization. To test whether NBD1 is able to dimerize *in vivo*, the two-hybrid system of yeast was utilized. The yeast two-hybrid system is an effective  
30           tool for demonstrating the binding interaction of two protein domains. The system is based on the well-characterized interaction of the DNA-binding domain (BD) and

transcription-activation domain (AD) of the GAL4 transcription factor of yeast. The association of these two domains within the GAL4 protein results in the specific initiation of transcription of a reporter gene in yeast, but when these domains are expressed in yeast as separate domains, neither is capable of transcriptional activation in the absence of  
5 specific interaction with the other. The two-hybrid system was used to devise a phenotypic assay for the binding of the CFTR NBD1 domain to itself.

The DNA sequence encoding wildtype CFTR NBD1 T351-F650 was cloned in frame into the carboxy-terminus of the GAL4 DNA-binding domain on a yeast plasmid pBD-GAL4 (Stratagene). This plasmid (pBDGAL4-WT), contains a fusion protein  
10 consisting of the GAL4 DNA binding domain fused to CFTR NBD1 expressed under the control of the yeast ADH1 promoter and also contains the yeast selectable marker TRP1 and the 2 $\mu$  origin of replication. The same segment of CFTR NBD1 was also cloned in frame into the GAL 4 activation domain on pADGAL4 (with the yeast selectable marker LEU2 and 2 $\mu$  origin). This plasmid (pADGAL4-WT) contains a fusion protein consisting  
15 of the GAL transcription-activation domain fused to NBD1 expressed under the regulation of the ADH1 promoter, and also contains the LEU2 gene of yeast and the 2 $\mu$  origin of replication.

The two plasmids were transformed into yeast strain YRG2 to produce YRG2-WT. The YRG2 strain has the endogenous GAL4 transcription factor deleted and has  
20 auxotrophies *trp1*, *leu2*, and *his3*. Association of the two fusion proteins mediated by the interaction of NBD1 domains on each protein results in the transcriptional activation of the reporter gene, HIS3 that is regulated by GAL4 in YRG2. Activation of the HIS3 gene in yeast allows the YRG strain to grow on media lacking histidine, conferring a HIS+ phenotype. As shown in Figures 2A-2C, interaction between the NBD1 fusions in YRG-  
25 WT results in a HIS+ phenotype at both 21°C and 37°C. The wildtype CFTR NBD1 segment is thus able to self-associate and form dimers.

The  $\Delta$ F508 mutation was introduced into both pBDGAL4-WT and pADGAL4-WT, creating pBDGAL4- $\Delta$ F and pADGAL4- $\Delta$ F, respectively, and both plasmids were  
30 used to transform YRG2 (producing YRG- $\Delta$ F). Unlike the YRG-WT strain, the YRG- $\Delta$ F strain was phenotypically HIS- when tested for growth on selective media lacking histidine at 37°C. However, when tested for growth on selective media lacking histidine

at 21°C the YRG2 strain was phenotypically HIS<sup>+</sup>. Thus, the  $\Delta$ F508 mutation conferred a temperature-sensitive HIS<sup>+</sup> phenotype to the yeast strain containing pAD $\Delta$ F and pBD $\Delta$ F, analogous to the temperature-sensitive processing defect observed for CFTR $\Delta$ F508. A strain containing pBD $\Delta$ F and pADWT (YRG- $\Delta$ F/WT) was also temperature-sensitive, indicating that heterodimers between a mutant  $\Delta$ F508 NBD1 and a wildtype NBD1 could form at the permissive temperature (21°C), but not at the nonpermissive temperature (37°C). These results indicate that the  $\Delta$ F508 mutation prevents the dimerization of NBD1 in a temperature-sensitive manner. Further, temperature-sensitive dimerization of mutant NBD1 containing the  $\Delta$ F508 mutation is rescued by a concentration of 1.5M glycerol in the growth media (Figure 2C), indicating that the same interventions that correct the CFTR $\Delta$ F508 folding defect in animal cell cultures (Sato, 1996; Brown, 1996) also restored dimerization of the NBD1 in the yeast two-hybrid system.

To further assess the effect of CF mutations on dimerization of NBD1, CF-causing mutations were introduced into the pBD-WT and pAD-WT constructs and expressed these constructs in YRG2. As shown in Figures 2A-2C, the CF-causing mutations  $\Delta$ I507 and S549R result in defective NBD1 dimerization. Like  $\Delta$ F508, these mutations result in defective processing of CFTR. Another CF-causing mutations, G551D was also introduced into NBD1 within pBD-WT and pAD-WT, and did not result in defective NBD1 dimerization in yeast. In CFTR, the G551D mutation does not result in defective processing, but instead affects CFTR function. Defective dimerization of NBD1 was thus associated only with CF mutations that cause defective processing. These results suggest that the molecular defects associated with CF mutations are effectively modeled in yeast strain YRG2- $\Delta$ F.

The present invention is based upon the discovery that dimerization of NBD1 between CFTR protein monomers is required for processing of the CFTR, and that processing of CFTR $\Delta$ F508 is defective because of an inability of mutant CFTR protein to form dimers. It follows that interventions that restore dimerization of mutant CFTR NBD1 containing the  $\Delta$ F508 mutation, should also restore processing of CFTR $\Delta$ F508. A small molecule drug or other compound that promotes dimerization of NBD1 would thus constitute a drug intervention that restores CFTR $\Delta$ F508 processing and function.

Example 4 – Preparation of revertant mutants that restore dimerization in  $\Delta F508$ 

Second-site revertant mutations in NBD1 that restore dimerization of NBD1 would constitute a genetic intervention that restores CFTR $\Delta F508$  processing and function. Revertants of the  $\Delta F508$  dimerization defect were identified using the two-hybrid system. Revertant mutations would be expected to restore defective dimerization in yeast, and also correct the processing defect of CFTR $\Delta F508$  when introduced into a CFTR $\Delta F508$  cDNA allele expressed in mammalian cells. In order to isolate revertants of the  $\Delta F508$  dimerization defect, the fact that the formation of dimers between a wildtype NBD1 and mutant NBD1 $\Delta F508$  is defective at the nonpermissive temperature (Figures 2A-2C), as it is in YRG2- $\Delta F$  (where both NBD1 fusion proteins contain  $\Delta F508$ ) was exploited. If grown at the permissive temperature however, this “heterozygote” strain is HIS<sup>+</sup> indicating that the mutant NBD1 is able to assume a wildtype-like conformation and form dimers with the wildtype NBD1 domain if allowed to fold at low temperature. Revertants of the  $\Delta F508$  dimerization defect can therefore be selected as mutations that occur in the mutant NBD1 and cause it to assume a configuration that is more like wildtype CFTR NBD1 at the nonpermissive temperature. The strategy for isolation of a  $\Delta F508$  dimerization revertant therefore involved *in vitro* mutagenesis of pBD- $\Delta F$  plasmid DNA, and subsequent transformation of this mutagenized DNA into YRG2 yeast containing the pAD-WT plasmid. It was anticipated that second-site mutations within the mutant NBD1 containing  $\Delta F508$  could restore heterodimer formation with wildtype NBD1, giving rise to transformants that were HIS<sup>+</sup> at 37°C. Two revertant mutations of the  $\Delta F508$  dimerization defect, G550E and I539T, were identified as revertants of the  $\Delta F508$  dimerization defect in the two-hybrid system. I539T and G550E were introduced into plasmids pBD- $\Delta F$  and pAD- $\Delta F$ , transformed YRG2 and assayed the HIS phenotype of resulting transformants. As indicated in Figure 3, the HIS<sup>+</sup> phenotype of these strains (containing pBD- $\Delta F$ /I539T and pAD- $\Delta F$ /I539T or containing pBD- $\Delta F$ /G550E and pAD- $\Delta F$ /G550E) indicates that the I539T and G550E mutations restore *in vivo* dimerization of mutant NBD1 containing  $\Delta F508$ .

To demonstrate that  $\Delta F508$  revertant mutations I539T and G550E restore processing of CFTR $\Delta F508$  in mammalian cells, CFTR $\Delta F508$  cDNA alleles containing either I539T or G550E were constructed for expression in mammalian cells. The I539T

and G550E mutations were introduced into the plasmid expression vector pSWICK (Swick *et al.*, 1992) (producing pSWICK-CFTR $\Delta$ F508/I539T and pSWICK-CFTR $\Delta$ F508/G550E) using oligonucleotide mutagenesis and the polymerase chain reaction. The pSWICK-CFTR $\Delta$ F508/I539T plasmid DNA (15  $\mu$ g.) and pSWICK-CFTR $\Delta$ F508/G550E DNA (15  $\mu$ g.) were then each mixed with 15  $\mu$ g. of pcDNA3.1 plasmid DNA (Invitrogen), which contains the gene encoding Zeocin (Invitrogen) resistance. Each mixture of plasmid DNAs was then complexed with DMRIE-C lipid (Gibco) and used to transfect Fisher Rat Thyroid cells to obtain stable cell line transformants. Transformants were selected as Zeocin resistant colonies, that were then expanded and subcloned. Cell lines expressing either CFTR $\Delta$ F508/I539T, CFTR $\Delta$ F508/G550E, wildtype CFTR or mutant CFTR $\Delta$ F508 were then grown as monolayers in Minicells, and mounted into Ussing chambers to assay for cAMP-stimulated chloride channel activity (Sheppard *et al.*, 1994). As shown in Figure 4, a control cell line expressing wildtype CFTR produces a cAMP-stimulated chloride current of approximately 67  $\mu$ Amps/cm<sup>2</sup>, whereas a cell line expressing CFTR $\Delta$ F508 produces approximately 1.7  $\mu$ Amps/cm<sup>2</sup>. The cell lines expressing CFTR $\Delta$ F508/I539T and CFTR $\Delta$ F508/G550E each produced a significantly higher level of cAMP-stimulated chloride current (approximately 26  $\mu$ Amps/cm<sup>2</sup> and 17  $\mu$ Amps/cm<sup>2</sup>, respectively) as compared to a cell line expressing CFTR $\Delta$ F508, indicating that both revertant mutations restore CFTR $\Delta$ F508 processing leading to functional CFTR $\Delta$ F508 protein at the plasma membrane. These results indicate that a genetic intervention to correct dimerization of a mutant NBD1 results in correction of the CFTR $\Delta$ F508 processing defect and increased CFTR $\Delta$ F508 cAMP-stimulated chloride channel activity .

#### 25 Example 5 – Screening for molecules to correct the CFTR $\Delta$ F508 dimerization defect

As a means for identifying small molecule candidate drugs that correct the CFTR $\Delta$ F508 dimerization defect, the methods of the present invention were used to screen plants for compounds with activity to increase CFTR $\Delta$ F508 chloride channel processing and function. The YRG2- $\Delta$ F strain was used to identify a plant of the genus Trichilia that produces a compound with activity to reverse the dimerization defect in YRG2- $\Delta$ F. An extract was prepared from leaf material of the plant and fractionated by



standard methods. Fractions were assayed using the YRG2- $\Delta$ F strain to detect activity (*i.e.*, activity to reverse the NBD1 dimerization defect resulting from the  $\Delta$ F508 mutation). A compound with activity was purified from the plant extract and designated TS3. The TS3 compound was then assayed for activity to correct the CFTR $\Delta$ F508 chloride channel defect in mammalian cells.

The TS3 compound was added at a concentration of 40  $\mu$ M to the cell culture media of FRT cells grown in Millicells for three days. Cells were incubated in the presence of TS3 for an additional 72 hours. To assay cells for CFTR $\Delta$ F508 cAMP-stimulated activity, the monolayers were mounted into Ussing chambers, cAMP agonists were added and the resulting peak change in chloride conductance was measured (Sheppard *et al.*, 1994). Table 3 shows the mean cAMP-stimulated currents for untreated CFTR $\Delta$ F508 expressing cells (n=4), and for CFTR $\Delta$ F508 cells treated with TS3 for 48 hours (n=4). The results show that incubation of cells expressing the mutant CFTR $\Delta$ F508 chloride channel with TS3 results in an approximately 70% increase in cAMP-stimulated chloride channel activity as compared to untreated cells expressing CFTR $\Delta$ F508. This data indicates that the TS3 compound has activity to correct the molecular defect of CFTR $\Delta$ F508 leading to increased functional activity at the plasma membrane. The data additionally demonstrate that the YRG2- $\Delta$ F yeast strain is an effective means to identify and purify compounds that have activity to correct the molecular defect causing cystic fibrosis.

<b>Table 3.</b>	
Effect of compound TS3 on cAMP-stimulated Cl <sup>-</sup> current from FRT cells expressing CFTR $\Delta$ F508.	
	$\Delta I_{CL}/cm^2$
TS3 (40 $\mu$ m)	2.06 $\pm$ 0.13 (n=4)
No TS3	1.2 $\pm$ 0.11 (n=4)

Significance was calculated using the student's t-test (p<0.001).

It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

References

- U.S. Patent No. 5,283,173
- U.S. Patent No. 5,468,614
- 5 U.S. Patent No. 5,543,399
- Aronheim A., E. Zandi, H. Hennemann, S. J. Elledge, M. Karin (1997) "Isolation of an AP-1 repressor by a novel method for detecting protein-protein interactions" *Mol Cell Biol* 17(6):3094-3102.
- 10 Berlin, V. (1997) "Detecting protein interactions mediated by small molecule small ligands" *The Yeast Two-Hybrid System*, edited by Paul L. Bartel & Stanley Fields, Oxford University Press, New York.
- Brown, C. R., L. Q. Hong-Brown, J. Biwersi, A. S. Verkman, W. J. Welch (1996)
- 15 "Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein" *Cell Stress Chaperones* 1:117-125.
- Cheng, S. H., R. J. Gregory, J. Marshall, S. Paul, D.W. Souza, G. A. White, C. R. O'Riordan, A. E. Smith (1990) "Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis" *Cell* 63:827-834.
- 20 Denning, G. M., M. P. Anderson, J. Amara, J. Marshall, A. E. Smith, M. J. Welsh (1992) "Processing of mutant CFTR( $\Delta$ F508) is temperature sensitive" *Nature* 358:761-764.
- 25 Flotte, T. R., S. A. Afione, P. L. Zeitlin (1994) "Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration" *Am J Respir Cell Mol Biol* 11:517-521.
- 30 Gregory, R. J., D. P. Rich, S. H. Cheng, D. W. Souza, S. Paul, P. Manavalan, M. P. Anderson, M. J. Welsh, A. E. Smith (1991) "Maturation and function of cystic fibrosis transmembrane conductance regulator variants bearing mutations in putative nucleotide-binding domains 1 and 2" *Mol Cell Biol* 11:3886-3893.
- 35 Johnson and Varshavsky (1997) "Split ubiquitin, a sensor of protein interactions in vitro" *The Yeast Two-Hybrid System*, edited by Paul L. Bartel & Stanley Fields, Oxford University Press, New York.
- 40 Karimova G., J. Pidoux, A. Ullmann, D. Ladant (1998) "A bacterial two-hybrid system based on a reconstituted signal transduction pathway" *Proc Natl Acad Sci USA* 95(10):5752-5756.
- Keegan *et al.* (1986) *Science* 231:699-704.

- Kerem, B.-S., J. M. Rommens, J.-A. Buchanan, D. Markiewicz, T. K. Cox, A. Chakravarti, M. Buchwald, L.-C. Tsui (1989) "Identification of the Cystic Fibrosis Gene: Genetic Analysis" *Science* 245:1073-1080.
- 5 Ma and Ptashne (1987) *Cell* 48:847-853.
- Riordan, J. R., J. M. Rommens, B-S Kerem, N. Alon, R. Rozmahel, Z. Grzelczak, J. Zielenski, S. Lok, N. Plavsic, J-L Chou, M. L. Drumm, M. C. Iannuzzi, F. S. Collins, L.-C. Tsui (1989) "Identification of the Cystic Fibrosis Gene: Cloning and characterization of complementary DNA" *Science* 245:1066-1073.
- 10
- Rommens, J. M., M. C. Iannuzzi, B-S Kerem, M. L. Drumm, G. Melmer, M. Dean, R. Rozmahel, J. L. Cole, D. Kennedy, N. Hidaka, M. Zsiga, M. Buchwald, J. R. Riordan, L.-C. Tsui, F. Collins (1989) "Identification of the Cystic Fibrosis gene: Chromosome walking and jumping" *Science* 245:1059-1065.
- 15
- Sato, S., C. L. Ward, M. E. Krouse, J. J. Wine, R. R. Kopito (1996) "Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation" *J Biol Chem* 271:635-638.
- 20
- Sheppard, D. N., D. P. Rich, L. S. Ostedgaard, R. J. Gregory, A. E. Smith, M. J. Welsh. (1993) "Mutations in CFTR associated with mild-disease-form Cl<sup>-</sup> channels with altered pore properties" *Nature* 362:160-164.
- 25
- Sheppard, D. N., M. R. Carson, L. S. Ostedgaard, G. M. Denning, M. J. Welsh (1994) "Expression of cystic fibrosis transmembrane conductance regulator in a model epithelium" *Am J Physiol* 266:L405-413.
- 30
- Swick, A. G., M. Janicot, T. Cheneval-Kastelic, J. C. McLenithan, M. D. Lane (1992) "Promoter-cDNA-directed heterologous protein expression in *Xenopus laevis* oocytes" *Proc Natl Acad Sci USA* 89:1812-1816.
- 35
- Teem, J. L., H. A. Berger, L. O. Sstedgaard, D. P. Rich, L-C Tsui, M. J. Welsh (1993) "Identificatioin of revertants for the cystic fibrosis  $\Delta F508$  mutation using STE6-CFTR chimeras in yeast" *Cell* 73:335-346.
- 40
- Teem, J. L., M. Carson, M.J. Welsh (1996) "Mutation of R555 in CFTR- $\Delta F508$  Enhances Function and Partially Corrects Defective Processing" *Receptors and Channels* 4:63-72.
- 45
- Welsh, M. J., A. E. Smith, J. Zabner, D. P. Rich, S. M. Graham, R. J. Gregory, B. M. Pratt, R. A. Moscicki (1994) "Cystic fibrosis gene therapy using an adenovirus vector: in vivo safety and efficacy in nasal epithelium" *Hum Gene Ther* 5:209-219.
- Welsh, M. J., A. E. Smith (1995) "Cystic fibrosis" *Sci Am* 273:52-59.

- Zabner, J., L. A. Couture, R. J. Gregory, S. M. Graham, A. E. Smith, M. J. Welsh (1993) "Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis" *Cell* 75:207-216.
- 5 Zabner, J., S. H. Cheng, D. Meeker, J. Launspach, R. Balfour, M. A. Perricone, J. E. Morris, J. Marshall, A. Fasbender, A. E. Smith, M. J. Welsh (1997) "Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo" *J Clin Invest* 100:1529-1537.

Claims

I claim:

- 1           1. A method for detecting or determining the interaction of a first CFTR  
2 polypeptide with a second CFTR polypeptide, said method comprising:
  - 3           (a) providing a first polynucleotide encoding a fusion protein comprising all or a  
4 portion of a first CFTR polypeptide and a DNA binding domain of a transcriptional  
5 activator that can bind to a site on a detectable gene;
  - 6           (b) providing a second polynucleotide encoding a fusion protein comprising all or  
7 a portion of a second CFTR polypeptide and a transcriptional activation domain of a  
8 transcriptional activator that can activate transcription of said detectable gene;
  - 9           (c) incorporating said first and second polynucleotide into a host cell comprising  
10 said detectable gene wherein transcription of said detectable gene is under control of said  
11 transcriptional activator;
  - 12           (d) expressing said polynucleotide encoding said first CFTR polypeptide and said  
13 second CFTR polypeptide under conditions in which said detectable gene is expressed  
14 when said first CFTR polypeptide and said second CFTR polypeptide interact; and  
15           (e) detecting transcription of said detectable marker gene or expression of the gene  
16 product of said detectable gene.
  
- 1           2. The method according to claim 1, wherein said host cell is a yeast cell.
  
- 1           3. The method according to claim 2, wherein said yeast cell is *Saccharomyces*.
  
- 1           4. The method according to claim 1, wherein the host cell is a mammalian cell.
  
- 1           5. The method according to claim 1, wherein said CFTR polypeptide is a  
2 mammalian CFTR polypeptide.
  
- 1           6. The method according to claim 1, wherein said CFTR polypeptide comprises  
2 amino acid residue 351 through 650 of the human CFTR protein sequence.

1           7. The method according to claim 1, wherein said detectable gene is selected from  
2 the group consisting of *lacZ*, *LEU2* and *HIS3*.

1           8. The method according to claim 1, wherein said DNA binding domain comprises  
2 the DNA binding domain of GAL4 protein.

1           9. The method according to claim 1, wherein said transcriptional activation domain  
2 comprises the transcriptional activation domain of GAL4 protein.

1           10. The method according to claim 1, wherein said CFTR polypeptides are mutant  
2 CFTR polypeptides.

1           11. The method according to claim 1, wherein said CFTR polypeptide comprises  
2 a mutation in the first nucleotide binding domain (NBD1).

1           12. The method according to claim 10, wherein said mutant CFTR polypeptide  
2 contains a  $\Delta F508$  mutation.

1           13. The method according to claim 1, wherein said CFTR polypeptide is a wild  
2 type CFTR polypeptide.

1           14. A method of identifying a compound that facilitates interaction of CFTR  
2 polypeptides, said method comprising:

3           (a) contacting a host cell with said compound, wherein said host cell comprises  
4 a polynucleotide encoding a fusion protein comprising all or a portion of a first CFTR  
5 protein and a DNA binding domain of a transcriptional activator that can bind to a site on  
6 a detectable gene, and a polynucleotide encoding a fusion protein comprising all or a  
7 portion of a second CFTR polypeptide and a transcriptional activation domain of a  
8 transcriptional activator that can activate transcription of a detectable gene, wherein said  
9 host cell further comprises said detectable gene wherein transcription of said detectable  
10 gene is under control of said transcriptional activator,

11 wherein said first and second CFTR polypeptides comprise a mutation that reduces or  
12 prevents interaction of said fusion proteins;

13 (b) expressing said polynucleotide encoding said first CFTR polypeptide and said  
14 second CFTR polypeptide under conditions in which said detectable gene is expressed  
15 when said first CFTR polypeptide and said second CFTR polypeptide interact; and,

16 (c) determining whether said detectable gene is expressed in said host cell at a  
17 level greater than the level of expression observed in said host cell in the absence of said  
18 compound.

1 15. The method according to claim 14, wherein said host cell is a yeast cell.

1 16. The method according to claim 15, wherein said yeast cell is *Saccharomyces*.

1 17. The method according to claim 14, wherein the host cell is a mammalian cell.

1 18. The method according to claim 14, wherein said CFTR polypeptide is a  
2 mammalian CFTR polypeptide.

1 19. The method according to claim 14, wherein said CFTR polypeptide comprises  
2 amino acid residue 351 through 650 of the human CFTR protein sequence.

1 20. The method according to claim 14, wherein said detectable gene is selected  
2 from the group consisting of *lacZ*, *LEU2* and *HIS3*.

1 21. The method according to claim 14, wherein said DNA binding domain  
2 comprises the DNA binding domain of GAL4 protein.

1 22. The method according to claim 14, wherein said transcriptional activation  
2 domain comprises the transcriptional activation domain of GAL4 protein.



1           23. The method according to claim 14, wherein said CFTR polypeptides are  
2 mutant CFTR polypeptides.

1           24. The method according to claim 14, wherein said CFTR polypeptide comprises  
2 a mutation in the first nucleotide binding domain (NBD1).

1           25. The method according to claim 23, wherein said mutant CFTR polypeptide  
2 contains a  $\Delta F508$  mutation.

1           26. The method according to claim 14, wherein said compound is present in a  
2 plant and said host cells is contacted with a tissue sample from said plant.

1           27. The method according to claim 26, wherein said tissue sample is a leaf disc  
2 from said plant.

1           28. The method according to claim 14, wherein said host cell is contacted with  
2 a sample present or absorbed on a filter paper disc.

1           29. The method according to claim 14, wherein increased growth of said host  
2 cells is used for determining whether said detectable gene is expressed in said host cells  
3 at a level greater than the level of expression observed in said host cells in the absence of  
4 said compound.

1           30. The method according to claim 14, wherein said CFTR polypeptide is a wild  
2 type CFTR polypeptide.

1           31. The method according to claim 14, wherein said compound is selected from  
2 the group consisting of a polypeptide or a biologically active fragment thereof, an  
3 antibody or antigen binding fragment thereof, and a polynucleotide.

1           32. A method for detecting or determining the interaction of a first CFTR  
2 polypeptide with a second CFTR polypeptide, said method comprising (a) providing a  
3 fusion protein comprising all or a portion of a first CFTR protein and a DNA binding  
4 domain of a transcriptional activator that can bind to a site on a detectable marker gene;  
5 (b) providing a second fusion protein comprising all or a portion of a second CFTR  
6 polypeptide and a transcriptional activation domain of a transcriptional activator that can  
7 activate transcription of the detectable marker gene; (c) contacting said first fusion protein  
8 and said second fusion protein under conditions where if said first fusion protein and said  
9 second fusion protein interact then said interaction causes said transcriptional activation  
10 domain to activate transcription of said detectable marker gene; and (d) detecting  
11 transcription of said detectable marker gene or expression of the gene product of said  
12 detectable marker gene.

1           33. The method according to claim 32, wherein said host cell is a yeast cell.

1           34. The method according to claim 33, wherein said yeast cell is *Saccharomyces*.

1           35. The method according to claim 32, wherein the host cell is a mammalian cell.

1           36. The method according to claim 32, wherein said CFTR polypeptide is a  
2 mammalian CFTR polypeptide.

1           37. The method according to claim 32, wherein said CFTR polypeptide comprises  
2 amino acid residue 351 through 650 of the human CFTR protein sequence.

1           38. The method according to claim 32, wherein said detectable gene is selected  
2 from the group consisting of *lacZ*, *LEU2* and *HIS3*.

1           39. The method according to claim 32, wherein said DNA binding domain  
2 comprises the DNA binding domain of GAL4 protein.

1           40. The method according to claim 32, wherein said transcriptional activation  
2 domain comprises the transcriptional activation domain of GAL4 protein.

1           41. The method according to claim 32, wherein said CFTR polypeptides are  
2 mutant CFTR polypeptides.

1           42. The method according to claim 32, wherein said CFTR polypeptide comprises  
2 a mutation in the first nucleotide binding domain (NBD1).

1           43. The method according to claim 41, wherein said mutant CFTR polypeptide  
2 contains a  $\Delta$ F508 mutation.

1           44. The method according to claim 32, wherein said CFTR polypeptide is a wild  
2 type CFTR polypeptide.

1           45. A host cell comprising a polynucleotide encoding a fusion protein comprising  
2 all or a portion of a first CFTR protein and a DNA binding domain of a transcriptional  
3 activator that can bind to a site on a detectable gene and a polynucleotide encoding a  
4 fusion protein comprising all or a portion of a second CFTR protein and a transcriptional  
5 activation domain of a transcriptional activator that can activate transcription of said  
6 detectable gene.

1           46. The method according to claim 45, wherein said host cell is a yeast cell.

1           47. The method according to claim 46, wherein said yeast cell is *Saccharomyces*.

1           48. The method according to claim 45, wherein the host cell is a mammalian cell.

1           49. The method according to claim 45, wherein said CFTR polypeptide is a  
2 mammalian CFTR polypeptide.

1           50. The method according to claim 45, wherein said CFTR polypeptide comprises  
2 amino acid residue 351 through 650 of the human CFTR protein sequence.

1           51. The method according to claim 45, wherein said detectable gene is selected  
2 from the group consisting of lacZ, *LEU2* and *HIS3*.

1           52. The method according to claim 45, wherein said DNA binding domain  
2 comprises the DNA binding domain of GAL4 protein.

1           53. The method according to claim 45, wherein said transcriptional activation  
2 domain comprises the transcriptional activation domain of GAL4 protein.

1           54. The method according to claim 45, wherein said CFTR polypeptides are  
2 mutant CFTR polypeptides.

1           55. The method according to claim 45, wherein said CFTR polypeptide comprises  
2 a mutation in the first nucleotide binding domain (NBD1).

1           56. The method according to claim 54, wherein said mutant CFTR polypeptide  
2 contains a  $\Delta$ F508 mutation.

1           57. The method according to claim 45, wherein said CFTR polypeptide is a wild  
2 type CFTR polypeptide.

1/2




FIG. 1




FIG. 2A

FIG. 2B

FIG. 2C




FIG. 3

2/2




FIG. 4

SEQUENCE LISTING

<110> Teen, John L.

<120> Materials and Methods for Detecting Interaction of CFTR Polypeptides

<130> FSU-100XC1

<140> (not yet assigned)

<141> 2000-10-06

<150> 60/157,996

<151> 1999-10-06

<150> 60/181,892

<151> 2000-02-11

<150> 60/182,373

<151> 2000-02-14

<160> 4

<170> PatentIn version 3.0

<210> 1

<211> 25

<212> DNA

<213> Homo sapien

<400> 1

cgcggaattc actcggcaat ttccc

<210> 2

<211> 28

<212> DNA

<213> Homo sapien

<400> 2

gcgccctgcag ttaagaacag aatgaaat

28

<210> 3

<211> 4443

<212> DNA

<213> Homo sapien

<220>

<221> gene

<222> (1)..(4443)

<400> 3

atgcagaggt cgcctctgga aaaggccagc gttgtctcca aacttttttt cagctggacc 60

agaccaatth tgaggaaagg atacagacag cgcctggaat tgtcagacat ataccaahtc 120

ccttctgttg attctgctga caatctatct gaaaaattgg aaagagaatg ggatagagag 180

ctggcttcaa agaaaaatcc taaactcatt aatgcccttc ggcgatgttt tttctggaga 240

tttatgttct atggaatctt tttatattta ggggaagtca ccaaagcagt acagcctctc 300

ttactgggaa gaatcatagc ttctatgac ccggataaca aggaggaacg ctctatcgcg 360



atztatctag gcataggctt atgccttctc tttattgtga ggacactgct cctacacca 420  
gccatTTTTg gccttcatca cattggaatg cagatgagaa tagctatggt tagtttgatt 480  
tataagaaga ctttaaagct gtcaagccgt gttctagata aaataagtat tggacaactt 540  
gtagtctcc tttccaacaa cctgaacaaa tttgatgaag gacttgcat ggacatttc 600  
gtgtggatcg ctctttgca agtggcactc ctcatggggc taatctggga gttgttacag 660  
gcgtctgcct tctgtggact tggtttctg atagtccttg ccctttttca ggctgggcta 720  
gggagaatga tgatgaagta cagagatcag agagctggga agatcagtga aagacttgtg 780  
attacctcag aatgattga aaatatccaa tctgttaagg catactgctg ggaagaagca 840  
atggaaaaaa tgattgaaaa cttaaagaaa acagaactga aactgactcg gaaggcagcc 900  
tatgtgagat acttcaatag ctacgccttc ttcttctcag ggttctttgt ggtgttttta 960  
tctgtgcttc cctatgcact aatcaaagga atcatcctcc ggaaaatatt caccaccatc 1020  
tcattctgca ttgttctgcg catggcggtc actcggcaat ttccctgggc tgtacaaaca 1080  
tggtatgact ctcttgagc aataaacaaa atacaggatt tcttacaana gcaagaatat 1140  
aagacattgg aatataactt aacgactaca gaagtagtga tggagaatgt aacagccttc 1200  
tgggaggagg gatttgggga attatttgag aaagcaaac aaaacaataa caatagaaaa 1260  
acttctaagtg gtgatgacag cctcttcttc agtaatttct cacttcttgg tactcctgtc 1320  
ctgaaagata ttaatttcaa gatagaaaga ggacagttgt tggcggttgc tggatccact 1380  
ggagcaggca agacttcact tctaagatg attatgggag aactggagcc ttcagagggt 1440  
aaaattaagc acagtggaag aatttcattc tgttctcagt tttcctggat tatgcctggc 1500  
accattaaag aaaatatcat ctttgggtgtt tcctatgatg aatatagata cagaagcgtc 1560  
atcaaagcat gccaaactaga agaggacatc tccaagtttg cagagaaaga caatatagtt 1620

cttggagaag gtggaatcac actgagtgga ggtcaacgag caagaatttc tttagcaaga 1680  
gcagtataca aagatgctga tttgtattta ttagactctc cttttggata cctagatggt 1740  
ttaacagaaa aagaaatatt tgaaagctgt gtctgtaaac tgatggctaa caaaactag 1800  
atthttggtca cttctaaaaat ggaacattta aagaaagctg acaaaatatt aatthttgcat 1860  
gaaggtagca gctatthttta tgggacattt tcagaactcc aaaatctaca gccagacttt 1920  
agctcaaaac tcatgggatg tgattcttht gaccaattta gtgcagaaa gaaatattca 1980  
atcctaactg agaccttaca ccgthttctca ttagaaggag atgctctgt ctctggaca 2040  
gaaacaaaaa aacaatctth taaacagact ggagagthttg gggaaaaaag gaagaattct 2100  
atthtcaatc caatcaactc tatacgaaaa thttccattg tgcaaaagac tcccttaca 2160  
atgaatggca tcgaagagga thctgatgag cthtttagaga gaaggctgtc cttagtacca 2220  
gattctgagc agggagaggc gatactgcct cgcacagcg tgatcagcac tggccccacg 2280  
cttcaggcac gaaggaggca gtctgtctctg aacctgatga cacactcagt taaccaaggt 2340  
cagaacattc accgaaagac aacagcatcc acacgaaaag tgtcactggc ccctcaggca 2400  
aacttgactg aactggatat atattcaaga aggttatctc aagaaactgg cttggaaata 2460  
agtgaagaaa ttaacgaaga agacttaaag gagtgcttht ttgatgatat ggagagcata 2520  
ccagcagtga ctacatggaa cacatactt cgatatatta ctgtccaca gagcttaatt 2580  
thttgtctaa thttggtgctt agtaathttt ctggcagagg tggctgctc thttggtgtg 2640  
ctgtggctcc ttgaaacac tcctcttcaa gacaaaggga atagtactca tagtagaaat 2700  
aacagctatg cagtgattat caccagcacc agttcgtatt atgtgthttta catttacgtg 2760  
ggagtagccg acactthtct tgctatggga thcttcagag gtctaccact ggtgcatact 2820  
ctaatcacag tgtcgaatth thtacaccac aaatgttac atthctgttct tcaagcacct 2880

atgtcaacc tcaacacggt gaaagcaggt gggattctta atagattctc caaagatata 2940  
gcaatthttg atgaccttct gcctcttacc atatthtgact tcatccagtt gttattaatt 3000  
gtgattggag ctatagcagt tgtcgcagtt ttacaacctt acatctthgt tgcaacagtg 3060  
ccagtgatag tggctthttat tatgthtgaga gcatatthtc tccaaacctc acagcaactc 3120  
aaacaactgg aatctgaagg caggagtcca atthttcactc atctthgttac aagctthaaa 3180  
ggactatgga cacttcgtgc cttcggacgg cagccttact ttgaaactct gttccacaaa 3240  
gctctgaatt tacatactgc caactggthc ttgtacctgt caaactgcg ctgthttcaa 3300  
atgagaatag aatgaththt tgtcatcttc thcattgctg ttaccttcat thccaththta 3360  
acaacaggag aaggagaagg aagagthggt attatctga cthtagccat gaatatcatg 3420  
agtacattgc agthggctgt aaactccagc atagatgthg atagctthgat gcgatctgtg 3480  
agccgagtct thaatthcat tgacatgcca acagaaggta aacctaccaa gtcaaccaa 3540  
ccatacaaga atggccaact ctcgaaagth atgaththtg agaathcaca cgtgaagaaa 3600  
gatgacatct ggcctcagg gggccaaatg actgtcaaag atctcacagc aaaatacaca 3660  
gaaggtggaa atgcatatt agagaacatt thctthctca thagtctgg ccagagggthg 3720  
ggcctctthg gaagaactgg atcagggag agthactthgt thcagctth ththgacta 3780  
ctgaacactg aaggagaaat ccagatcgat ggtgtgtctt gggaththcaat aactthgcaa 3840  
cagthggagga aagcctthg agthgatacca cagaaagth thathththtc tggaacath 3900  
agaaaaact thgatcccta tgaacagthg agthgatcaag aathatggaa agththcagat 3960  
gagththggc thcagatctgt gatagaacag ththctggga agctthgact thgtcctthgtg 4020  
gatggggct gthtcctaag ccatggccac aagcagthga thgtgctthg tagatctgth 4080  
ctcagthagg cgaagathct gthgctthgat gaaccagth cthaththgga thcagthaca 4140

taccaaataa ttagaagaac tctaaaacaa gcatttgctg attgcacagt aattctctgt 4200  
 gaacacagga tagaagcaat gctggaatgc caacaatttt tggatcataga agagaacaaa 4260  
 gtgcggcagt acgattccat ccagaaactg ctgaacgaga ggagcctctt ccggcaagcc 4320  
 atcagcccct ccgacagggt gaagctcttt ccccaccgga actcaagcaa gtgcaagtct 4380  
 aagccccaga ttgctgctct gaaagaggag acagaagaag aggtgcaaga tacaaggctt 4440  
 tag 4443

<210> 4

<211> 1480

<212> PRT

<213> Homo sapien

<220>

<221> PEPTIDE

<222> (1)..(1480)

<400> 4

Met	Gln	Arg	Ser	Pro	Leu	Glu	Lys	Ala	Ser	Val	Val	Ser	Lys	Leu	Phe
1				5					10					15	
Phe	Ser	Trp	Thr	Arg	Pro	Ile	Leu	Arg	Lys	Gly	Tyr	Arg	Gln	Arg	Leu
			20					25					30		
Glu	Leu	Ser	Asp	Ile	Tyr	Gln	Ile	Pro	Ser	Val	Asp	Ser	Ala	Asp	Asn
		35					40					45			
Leu	Ser	Glu	Lys	Leu	Glu	Arg	Glu	Trp	Asp	Arg	Glu	Leu	Ala	Ser	Lys
						50		55							60

Lys Asn Pro Lys Leu Ile Asn Ala Leu Arg Arg Cys Phe Phe Trp Arg  
 65 70 75 80

Phe Met Phe Tyr Gly Ile Phe Leu Tyr Leu Gly Glu Val Thr Lys Ala  
 85 90 95

Val Gln Pro Leu Leu Leu Gly Arg Ile Ile Ala Ser Tyr Asp Pro Asp  
 100 105 110

Asn Lys Glu Glu Arg Ser Ile Ala Ile Tyr Leu Gly Ile Gly Leu Cys  
 115 120 125

Leu Leu Phe Ile Val Arg Thr Leu Leu Leu His Pro Ala Ile Phe Gly  
 130 135 140

Leu His His Ile Gly Met Gln Met Arg Ile Ala Met Phe Ser Leu Ile  
 145 150 155 160

Tyr Lys Lys Thr Leu Lys Leu Ser Ser Arg Val Leu Asp Lys Ile Ser  
 165 170 175

Ile Gly Gln Leu Val Ser Leu Leu Ser Asn Asn Leu Asn Lys Phe Asp  
 180 185 190

Glu Gly Leu Ala Leu Ala His Phe Val Trp Ile Ala Pro Leu Gln Val  
 195 200 205

Ala Leu Leu Met Gly Leu Ile Trp Glu Leu Leu Gln Ala Ser Ala Phe  
 210 215 220

Cys Gly Leu Gly Phe Leu Ile Val Leu Ala Leu Phe Gln Ala Gly Leu  
 225 230 235 240

Gly Arg Met Met Met Lys Tyr Arg Asp Gln Arg Ala Gly Lys Ile Ser  
 245 250 255

Glu Arg Leu Val Ile Thr Ser Glu Met Ile Glu Asn Ile Gln Ser Val  
 260 265 270

Lys Ala Tyr Cys Trp Glu Glu Ala Met Glu Lys Met Ile Glu Asn Leu  
 275 280 285

Arg Gln Thr Glu Leu Lys Leu Thr Arg Lys Ala Ala Tyr Val Arg Tyr  
 290 295 300

Phe Asn Ser Ser Ala Phe Phe Phe Ser Gly Phe Phe Val Val Phe Leu  
 305 310 315 320

Ser Val Leu Pro Tyr Ala Leu Ile Lys Gly Ile Ile Leu Arg Lys Ile  
 325 330 335

Phe Thr Thr Ile Ser Phe Cys Ile Val Leu Arg Met Ala Val Thr Arg  
 340 345 350

Gln Phe Pro Trp Ala Val Gln Thr Trp Tyr Asp Ser Leu Gly Ala Ile  
 355 360 365

Asn Lys Ile Gln Asp Phe Leu Gln Lys Gln Glu Tyr Lys Thr Leu Glu  
 370 375 380

Tyr Asn Leu Thr Thr Thr Glu Val Val Met Glu Asn Val Thr Ala Phe  
 385 390 395 400

Trp Glu Glu Gly Phe Gly Glu Leu Phe Glu Lys Ala Lys Gln Asn Asn  
 405 410 415

Asn Asn Arg Lys Thr Ser Asn Gly Asp Asp Ser Leu Phe Phe Ser Asn  
 420 425 430

Phe Ser Leu Leu Gly Thr Pro Val Leu Lys Asp Ile Asn Phe Lys Ile  
 435 440 445

Glu Arg Gly Gln Leu Leu Ala Val Ala Gly Ser Thr Gly Ala Gly Lys  
 450 455 460

Thr Ser Leu Leu Met Met Ile Met Gly Glu Leu Glu Pro Ser Glu Gly  
 465 470 475 480

Lys Ile Lys His Ser Gly Arg Ile Ser Phe Cys Ser Gln Phe Ser Trp  
 485 490 495

Ile Met Pro Gly Thr Ile Lys Glu Asn Ile Ile Phe Gly Val Ser Tyr  
 500 505 510

Asp Glu Tyr Arg Tyr Arg Ser Val Ile Lys Ala Cys Gln Leu Glu Glu  
 515 520 525

Asp Ile Ser Lys Phe Ala Glu Lys Asp Asn Ile Val Leu Gly Glu Gly  
 530 535 540

Gly Ile Thr Leu Ser Gly Gly Gln Arg Ala Arg Ile Ser Leu Ala Arg  
 545 550 555 560

Ala Val Tyr Lys Asp Ala Asp Leu Tyr Leu Leu Asp Ser Pro Phe Gly  
 565 570 575

Tyr Leu Asp Val Leu Thr Glu Lys Glu Ile Phe Glu Ser Cys Val Cys  
 580 585 590

Lys Leu Met Ala Asn Lys Thr Arg Ile Leu Val Thr Ser Lys Met Glu  
 595 600 605

His Leu Lys Lys Ala Asp Lys Ile Leu Ile Leu His Glu Gly Ser Ser  
 610 615 620

Tyr Phe Tyr Gly Thr Phe Ser Glu Leu Gln Asn Leu Gln Pro Asp Phe  
 625 630 635 640

Ser Ser Lys Leu Met Gly Cys Asp Ser Phe Asp Gln Phe Ser Ala Glu  
 645 650 655

Arg Arg Asn Ser Ile Leu Thr Glu Thr Leu His Arg Phe Ser Leu Glu  
 660 665 670

Gly Asp Ala Pro Val Ser Trp Thr Glu Thr Lys Lys Gln Ser Phe Lys  
 675 680 685

Gln Thr Gly Glu Phe Gly Glu Lys Arg Lys Asn Ser Ile Leu Asn Pro  
 690 695 700

Ile Asn Ser Ile Arg Lys Phe Ser Ile Val Gln Lys Thr Pro Leu Gln  
 705 710 715 720

Met Asn Gly Ile Glu Glu Asp Ser Asp Glu Pro Leu Glu Arg Arg Leu  
 725 730 735

Ser Leu Val Pro Asp Ser Glu Gln Gly Glu Ala Ile Leu Pro Arg Ile  
 740 745 750

Ser Val Ile Ser Thr Gly Pro Thr Leu Gln Ala Arg Arg Arg Gln Ser  
 755 760 765

Val Leu Asn Leu Met Thr His Ser Val Asn Gln Gly Gln Asn Ile His  
 770 775 780

Arg Lys Thr Thr Ala Ser Thr Arg Lys Val Ser Leu Ala Pro Gln Ala  
 785 790 795 800

Asn Leu Thr Glu Leu Asp Ile Tyr Ser Arg Arg Leu Ser Gln Glu Thr  
 805 810 815

Gly Leu Glu Ile Ser Glu Glu Ile Asn Glu Glu Asp Leu Lys Glu Cys  
 820 825 830

Leu Phe Asp Asp Met Glu Ser Ile Pro Ala Val Thr Thr Trp Asn Thr  
 835 840 845

Tyr Leu Arg Tyr Ile Thr Val His Lys Ser Leu Ile Phe Val Leu Ile  
 850 855 860

Trp Cys Leu Val Ile Phe Leu Ala Glu Val Ala Ala Ser Leu Val Val  
 865 870 875 880

Leu Trp Leu Leu Gly Asn Thr Pro Leu Gln Asp Lys Gly Asn Ser Thr  
 885 890 895



His Ser Arg Asn Asn Ser Tyr Ala Val Ile Ile Thr Ser Thr Ser Ser  
                   900                                  905                                  910

Tyr Tyr Val Phe Tyr Ile Tyr Val Gly Val Ala Asp Thr Leu Leu Ala  
                   915                                  920                                  925

Met Gly Phe Phe Arg Gly Leu Pro Leu Val His Thr Leu Ile Thr Val  
                   930                                  935                                  940

Ser Lys Ile Leu His His Lys Met Leu His Ser Val Leu Gln Ala Pro  
 945                                  950                                  955                                  960

Met Ser Thr Leu Asn Thr Leu Lys Ala Gly Gly Ile Leu Asn Arg Phe  
                                   965                                  970                                  975

Ser Lys Asp Ile Ala Ile Leu Asp Asp Leu Leu Pro Leu Thr Ile Phe  
                                   980                                  985                                  990

Asp Phe Ile Gln Leu Leu Leu Ile Val Ile Gly Ala Ile Ala Val Val  
                   995                                  1000                                  1005

Ala Val Leu Gln Pro Tyr Ile Phe Val Ala Thr Val Pro Val Ile Val  
                   1010                                  1015                                  1020

Ala Phe Ile Met Leu Arg Ala Tyr Phe Leu Gln Thr Ser Gln Gln Leu  
 1025                                  1030                                  1035                                  1040

Lys Gln Leu Glu Ser Glu Gly Arg Ser Pro Ile Phe Thr His Leu Val  
                                   1045                                  1050                                  1055

Thr Ser Leu Lys Gly Leu Trp Thr Leu Arg Ala Phe Gly Arg Gln Pro  
                   1060                                  1065                                  1070

Tyr Phe Glu Thr Leu Phe His Lys Ala Leu Asn Leu His Thr Ala Asn  
                   1075                                  1080                                  1085

Trp Phe Leu Tyr Leu Ser Thr Leu Arg Trp Phe Gln Met Arg Ile Glu  
                   1090                                  1095                                  1100

Met Ile Phe Val Ile Phe Phe Ile Ala Val Thr Phe Ile Ser Ile Leu  
1105 1110 1115 1120

Thr Thr Gly Glu Gly Glu Gly Arg Val Gly Ile Ile Leu Thr Leu Ala  
1125 1130 1135

Met Asn Ile Met Ser Thr Leu Gln Trp Ala Val Asn Ser Ser Ile Asp  
1140 1145 1150

Val Asp Ser Leu Met Arg Ser Val Ser Arg Val Phe Lys Phe Ile Asp  
1155 1160 1165

Met Pro Thr Glu Gly Lys Pro Thr Lys Ser Thr Lys Pro Tyr Lys Asn  
1170 1175 1180

Gly Gln Leu Ser Lys Val Met Ile Ile Glu Asn Ser His Val Lys Lys  
1185 1190 1195 1200

Asp Asp Ile Trp Pro Ser Gly Gly Gln Met Thr Val Lys Asp Leu Thr  
1205 1210 1215

Ala Lys Tyr Thr Glu Gly Gly Asn Ala Ile Leu Glu Asn Ile Ser Phe  
1220 1225 1230

Ser Ile Ser Pro Gly Gln Arg Val Gly Leu Leu Gly Arg Thr Gly Ser  
1235 1240 1245

Gly Lys Ser Thr Leu Leu Ser Ala Phe Leu Arg Leu Leu Asn Thr Glu  
1250 1255 1260

Gly Glu Ile Gln Ile Asp Gly Val Ser Trp Asp Ser Ile Thr Leu Gln  
1265 1270 1275 1280

Gln Trp Arg Lys Ala Phe Gly Val Ile Pro Gln Lys Val Phe Ile Phe  
1285 1290 1295

Ser Gly Thr Phe Arg Lys Asn Leu Asp Pro Tyr Glu Gln Trp Ser Asp  
1300 1305 1310

Gln Glu Ile Trp Lys Val Ala Asp Glu Val Gly Leu Arg Ser Val Ile  
1315 1320 1325

Glu Gln Phe Pro Gly Lys Leu Asp Phe Val Leu Val Asp Gly Gly Cys  
1330 1335 1340

Val Leu Ser His Gly His Lys Gln Leu Met Cys Leu Ala Arg Ser Val  
1345 1350 1355 1360

Leu Ser Lys Ala Lys Ile Leu Leu Leu Asp Glu Pro Ser Ala His Leu  
1365 1370 1375

Asp Pro Val Thr Tyr Gln Ile Ile Arg Arg Thr Leu Lys Gln Ala Phe  
1380 1385 1390

Ala Asp Cys Thr Val Ile Leu Cys Glu His Arg Ile Glu Ala Met Leu  
1395 1400 1405

Glu Cys Gln Gln Phe Leu Val Ile Glu Glu Asn Lys Val Arg Gln Tyr  
1410 1415 1420

Asp Ser Ile Gln Lys Leu Leu Asn Glu Arg Ser Leu Phe Arg Gln Ala  
1425 1430 1435 1440

Ile Ser Pro Ser Asp Arg Val Lys Leu Phe Pro His Arg Asn Ser Ser  
1445 1450 1455

Lys Cys Lys Ser Lys Pro Gln Ile Ala Ala Leu Lys Glu Glu Thr Glu  
1460 1465 1470

Glu Glu Val Gln Asp Thr Arg Leu  
1475 1480